Research Progress and Challenges in Targeting GLUT1 in Tumors
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209225 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Taohua Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Glucose Transporter Type 1, Neoplasms. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
The solute carrier family 2 member 1 (SLC2A1), which encodes glucose transporter 1 (GLUT1), has long been recognized as a key driver of aerobic glycolysis in cancer. However, accumulating evidence has substantially expanded this view, revealing that GLUT1 functions not only as a critical mediator of metabolic reprogramming but also as an important regulator linking tumor metabolism to immune evasion. Notably, GLUT1 expression, regulation, and functional dependence are highly context-dependent across tumor types, disease states, and cellular compartments. Recent studies further link GLUT1-dependent glycolytic flux to immune regulation through glucose competition, lactate accumulation, and metabolite-dependent epigenetic programs within the tumor microenvironment. Reflecting this evolving understanding, therapeutic strategies targeting GLUT1 have progressed from simple metabolic inhibition to approaches that exploit tumor-specific metabolic dependencies and extend to regulated cell death, combination therapy, precision delivery, and selective modulation of malignant and non-malignant cellular compartments. These advances support a shift from expression-centered targeting toward strategies guided by functional GLUT1 dependence and cellular context, while recognizing the metabolic and physiological constraints that shape the therapeutic window. In this review, we systematically summarize recent advances in GLUT1 expression heterogeneity, multilayered regulatory networks, metabolic–immune crosstalk, diagnostic and prognostic relevance, and therapeutic targeting, and discuss how these insights may refine biomarker development, patient selection, and the clinical translation of GLUT1-directed precision metabolic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Förderung
- Natural Science Foundation of Hubei Province
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Chen, T., Peng, B., Yuan, X., Liu, Y., Zhang, J., Su, Y., Hu, G., Tao, Z., & Long, G. (2026). Research Progress and Challenges in Targeting GLUT1 in Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209225
Vancouver
Chen T, Peng B, Yuan X, Liu Y, Zhang J, Su Y, et al. Research Progress and Challenges in Targeting GLUT1 in Tumors. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209225
BibTeX
@article{Chen2026,
author = {Chen, Taohua and Peng, Bi and Yuan, Xinya and Liu, Yizhou and Zhang, Jianing and Su, Yizhen and Hu, Guangyuan and Tao, Zhen and Long, Guoxian},
title = {Research Progress and Challenges in Targeting GLUT1 in Tumors},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209225}
}
EUVIMED